β-blockade in sepsis: regulation of persisting sepsis-related tachycardia

Affiliations

¹ Department of Clinical, Anesthesiological and Cardiovascular Sciences, University of Rome La Sapienza, Rome, Italy. Electronic address: andrea.morelli@uniroma1.it.
² Department of Critical Care and Anaesthesia, University Hospital Birmingham, Birmingham, UK.
³ Department of Anesthesiology, Intensive Care, Emergency Medicine, Transfusion Medicine and Pain Therapy, Protestant Hospital of the Bethel Foundation, Bielefeld, Germany.

Comment

Andrea Morelli et al. Lancet Respir Med. 2020 Sep.

. 2020 Sep;8(9):833-834.

doi: 10.1016/S2213-2600(20)30063-1. Epub 2020 Mar 31.

¹ Department of Clinical, Anesthesiological and Cardiovascular Sciences, University of Rome La Sapienza, Rome, Italy. Electronic address: andrea.morelli@uniroma1.it.
² Department of Critical Care and Anaesthesia, University Hospital Birmingham, Birmingham, UK.
³ Department of Anesthesiology, Intensive Care, Emergency Medicine, Transfusion Medicine and Pain Therapy, Protestant Hospital of the Bethel Foundation, Bielefeld, Germany.

No abstract available

Comment on

Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, Nagano T, Morishima E, Matsuda N; J-Land 3S Study Group. Kakihana Y, et al. Lancet Respir Med. 2020 Sep;8(9):863-872. doi: 10.1016/S2213-2600(20)30037-0. Epub 2020 Mar 31. Lancet Respir Med. 2020. PMID: 32243865 Clinical Trial.